Augmedix
AUGX

Delisted

AUGX was delisted on the 3rd of October, 2024.

Back to rankings

About: Augmedix Inc is engaged in ambulatory/clinical/hospital segments of the U.S. patient care services market with products that address medical note documentation needs. The company's products cater to large and small healthcare organizations but can also be adopted by individual practitioners. The company products extract data from natural clinician-patient conversations and convert it in real time to medical notes, which are seamlessly transferred to the electronic health record (EHR). The company's revenues consist of service fees charged to its customers to subscribe to the company's remote medical documentation and clinical support products.

Employees: 1,430

Industrials Business Services

Financial journalist opinion

Commure Completes Merger with Augmedix

SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure.

Commure Completes Merger with Augmedix

24/7 Wall Street

7 AI Penny Stocks to Watch in October

If you're considering an investment in penny stocks, you should consider looking into those in markets with a lot of room for innovation.

7 AI Penny Stocks to Watch in October

STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger and Looming Vote on September 27, 2024, of Augmedix, Inc. - AUGX

NEW YORK , Sept. 6, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.

STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger and Looming Vote on September 27, 2024, of Augmedix, Inc. - AUGX

Zacks Investment Research

Augmedix, Inc. (AUGX) Reports Q2 Loss, Lags Revenue Estimates

Augmedix, Inc. (AUGX) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.12 per share a year ago.

Augmedix, Inc. (AUGX) Reports Q2 Loss, Lags Revenue Estimates

Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024

SAN FRANCISCO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended June 30, 2024.

Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024

STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Augmedix, Inc. – AUGX

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Augmedix , Inc . ( Nasdaq : AUGX ) , relating to its proposed merger with Commure, Inc. Under the terms of the agreement, Augmedix stock will be converted into the right to receive $2.35 in cash per share.

STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Augmedix, Inc. – AUGX

Why Is Augmedix (AUGX) Stock Up 150% Today?

Amid a sea of red in today's stock market, AI medical documentation and data solutions company Augmedix (NASDAQ: AUGX ) is certainly among the standout winners. Shares of AUGX stock have skyrocketed 150% in afternoon trading on a rather substantial announcement.

Why Is Augmedix (AUGX) Stock Up 150% Today?

AUGX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Augmedix, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Augmedix, Inc. (NASDAQ: AUGX) to Commure, Inc. for $2.35 per share in cash is fair to Augmedix shareholders. Halper Sadeh encourages Augmedix shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Augmedix and its boa.

AUGX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Augmedix, Inc. Is Fair to Shareholders

Shareholder Alert: Ademi LLP investigates whether Augmedix, Inc. has obtained a Fair Price for its Public Shareholders

MILWAUKEE , July 19, 2024 /PRNewswire/ -- Ademi LLP is investigating Augmedix (Nasdaq: AUGX) for possible breaches of fiduciary duty and other violations of law in its transaction with Commure. Click here to learn how to join our investigation https://www.ademilaw.com/case/augmedix-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Augmedix, Inc. has obtained a Fair Price for its Public Shareholders

Augmedix to Join Forces with Commure

Combination to Strengthen Ability to Deliver Frontier Ambient AI Solutions; Augmedix Stockholders to Receive $2.35 Per Share in All-Cash Acquisition by Commure Combination to Strengthen Ability to Deliver Frontier Ambient AI Solutions; Augmedix Stockholders to Receive $2.35 Per Share in All-Cash Acquisition by Commure

Augmedix to Join Forces with Commure

See News Rankings

Charts implemented using Lightweight Charts™